## **Special Issue**

# Advanced Research in Glaucoma: Treatment and Postoperative Approaches

## Message from the Guest Editor

Treatment goals for glaucoma have focused almost exclusively on lowering intraocular pressure (IOP) using drugs, laser therapy, or surgery. Surgery should be considered whenever medical or laser treatment is unlikely to maintain sight in the glaucomatous eye. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current treatment of glaucoma. It is important to investigate both the safety and the efficacy of IOP-lowering medication, laser surgery, or incisional surgery. I am confident that the results of such studies will be beneficial not only for glaucoma patients but also for physicians. The accumulation of these results will improve the quality of life in patients with glaucoma.

## **Guest Editor**

Dr. Kazuyuki Hirooka

Department of Ophthalmology and Visual Science, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan

## Deadline for manuscript submissions

closed (15 June 2023)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/122333

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## **Editor-in-Chief**

## Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

